

---

# INFLAMMATION AND CANCER PAIN: BASIC MECHANISMS

---

PRC & EAPC RN Pre-Congress Seminar:  
June 4-5, 2012 (Norway)

*Andrew Somogyi*

Discipline of Pharmacology

Faculty of Health Sciences

University of Adelaide

Australia

[andrew.somogyi@adelaide.edu.au](mailto:andrew.somogyi@adelaide.edu.au)



# Cancer and Pain

- Pain: a common symptom
- Increases as cancer progresses to advanced stage
- Progression of tumor growth → chemotaxis of **immune cells** (macrophages, T cells, dendritic cells) coexist with cancer cells → production of mediators also found in **inflamed tissue**
- Related to inflammation
- Tissue & Nerve compression → injury

# Background (1)

- Injury to tissues & nerves → inflammatory response
  - clear damaged cells, promote repair, contain pathogens
- 5 cardinal signs: **pain** .....
- **Pain**: nervous system process - tripartite system
  - Neurons-Immune Cells-Glia
  - Peripheral and Central mechanisms

## Background (2): Tissue Injury-TLRs

- Inflammation triggered by **innate immune system** of pattern recognition receptors (Toll Like Receptors[TLRs])
- TLRs: bind endogenous molecules (eg. heat shock protein) from damaged tissue


# What are these TLRs?

- Toll-Like Receptors: Family of pattern recognition receptors
- Monocytes, macrophages, dendritic cells, keratinocytes, mast cells, microglia, astrocytes, ....
- TLR4 (& TLR2) - recognises endogenous “danger signals”[HSP]
- TLR4
  - endotoxin (LPS) receptor;
  - Up regulated in neuropathic pain (animal models)
  - **If TLR4 expression is blocked**- pain does not develop
- **Signalling**: requires extracellular binding partner MD2 (myeloid differentiation factor) to associate before signalling commences

# Background (3): TLR Signaling

- Binding to MD2-TLRs → NF-κB activation (intracellular) →
    - Pro-inflammatory cytokine release
      - IL-1β, TNFα, IL-6
- 
- **Tissue Injury**: Resident immune cells, mast cells & macrophages also activated → proinflammatory cytokines, chemokines, vasodilators ...

# Tissue Injury-Immune Activation-Nociceptor Sensitization



Injury activates TLRs. Vasodilators released. T cells, neutrophils, monocytes migrate. Macrophages recruited. Inflammatory mediators released. Nerve terminals activated **Peripheral nociceptor sensitization**

Immune cells contribute to peripheral sensitization – release soluble factors interacting with nociceptors. Note: immune system also release factors promoting tissue recovery and inflammation suppression



*Ren & Dubner. Nature (Medicine) 16, 1267, 2010*

# Inflammatory Immune Mediators in Peripheral Neuropathic/Cancer Pain

TNF $\alpha$   
 IL-1 $\beta$   
 IL-6  
 NO  
 PGs  
 COX-2  
 NGF

## Peripheral Nerve Injury

Inflammatory Pain






# Background (5): Injury & CNS Activation

- Glia are activated- especially **deep tissue injury**
- Relayed to brain via peripheral immune activation, afferent nerve input, circulating cytokines, immune cell trafficking

# Background (6): Peripheral Immune Signals

- IL-6: messenger from periphery to brain
- Fractalkine (chemokine): sustained input from peripheral tissue
  - Deep muscle, joint & visceral tissue injury
- Infiltration immune cells into CNS → chronic pain
- Blood:brain barrier permeability compromised (P-gp)

# CNS: Glia- More than Just Brain




**Astrocytes:** ensheath neuronal synapses

**Microglia:** surveillance monitors for danger signals: stress, pain, infections

**Endogenous signal:** Heat shock protein, LPS


TLR activation  $\rightarrow$  IL-1 $\beta$ , IL-6, TNF $\alpha$

# Peripheral Injury Activation of Glia & Neurons: Dorsal Horn Spinal Cord



TLR activation by **LPS**, HSP of glia → IL-1β → modulation of NMDA on post synaptic neurons → **Central Sensitization**

# Nerve damage affects dorsal horn neurones: activation of glia: mediators



- IL-1β
- TNFα
- IL-6
- NO
- PG
- NGF

# Key Role of IL-1 $\beta$

- Key cytokine modulating microglia, astrocytes, neurons
- Selectively upregulated in astrocytes - spinal cord & other sites in animal models of cancer pain


R.-X. ZHANG,<sup>a\*</sup> B. LIU,<sup>a</sup> A. LI,<sup>a</sup> L. WANG,<sup>a</sup> K. REN,<sup>b</sup>  
J.-T. QIAO,<sup>c</sup> B. M. BERMAN<sup>a</sup> AND L. LAO<sup>a</sup>

**INTERLEUKIN 1 $\beta$  facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylation** Neurosci 154, 1533, 2008

- spinal IL-1 $\beta$  upregulated in this model

# How do Cytokines Cause Pain? IL-1 $\beta$

- phosphorylates NMDA receptor  $\rightarrow$  channel opening  $\rightarrow$   $\uparrow$  Ca $^{2+}$  influx  $\rightarrow$   $\uparrow$  NO &  $\uparrow$  PGE $_2$   $\rightarrow$  amplify excitability pain projection neurons
- Inhibits Glu reuptake
- Upregulates NMDA & AMPA receptors expression



# Inflammatory Biomarkers & Pain



PAIN® 152 (2011) 460–463

PAIN®

[www.elsevier.com/locate/pain](http://www.elsevier.com/locate/pain)

Clinical note

Cancer pain and its relationship to systemic inflammation: An exploratory study

Barry J.A. Laird<sup>a,\*</sup>, Angela C. Scott<sup>a</sup>, Lesley A. Colvin<sup>b</sup>, Amy-Louise McKeon<sup>a</sup>, Gordon D. Murray<sup>a</sup>,  
Kenneth C.H. Fearon<sup>a</sup>, Marie T. Fallon<sup>a</sup>

<sup>a</sup> University of Edinburgh, UK

<sup>b</sup> Western General Hospital, Edinburgh, UK

- CRP a valid serum biomarker of IL-6
- Positive correlation between log serum CRP and EORTC Pain Symptom Scale  
 $r = 0.126$  ( $P = 0.036$ );  $r = 0.163$  ( $P = 0.032$ )



# Cancer Pain Genetics: Cytokines (1)


- Reyes-Gibby et al (Cancer Epidemiol Biomarkers Prev 16, 2745, 2007)
  - Newly diagnosed NSCLC patients
  - *IL8* (-251T/A): associated with severe pain
    - OR=2.35 (1.10-5.03) TA/AA vs TT
  - No association: TNF- $\alpha$  (-308G/A), *IL6* (-174G/C)
  - IL-8 function: chemokine (CXCL8)
    - Mediator inflammatory response, promotes immune cell migration, induces astrocyte migration, microglia proliferation, induces TNF $\alpha$ , IL-6

# Cancer Pain Genetics: Cytokines (2)

- Reyes-Gibby et al (Cancer Epidemiol Biomarkers Prev 17, 3262, 2008)
  - Follow up previous study: 140 patients for pain treatment
  - TNF-a (-308G/A): associated with pain severity (P=0.03)
  - *IL6* (-174G/C): CC carriers associated with higher morphine equivalent dosing requirements
    - OR = 4.7 (1.2-12.01)
    - Mechanism(s) unclear- IL-6: Periphery pronociceptive; Central-pro – or antinociceptive; ↑ MOP, ↓ P-glycoprotein;

# Role of Glia in Pain Neuropathies


- Damaged Neuron, Virus, Diabetes ....



- Neurons release “danger signal” molecules: Heat-shock proteins
- Microglia mop-up molecules via toll-like receptors (TLR2, 4)- signalling
- Constant TLR signalling → ↓ (-ve) feedback → proinflammatory cytokines (IL-1)
- Prolonged proinflammatory pain response “allergy in dorsal horn **spinal cord**”

# Opioids also Dysregulate Glia

- Glia are activated
- Proinflammatory response
- **Enhance Pain** - decrease analgesia
- Increased tolerance, dependence, reward, etc



Dorsal horn glial activation from any source → enhanced pain

# Morphine activates neuroinflammation in a manner parallel to endotoxin

PNAS 109, 6325-6330, 2012

Xiaohui Wang<sup>a</sup>, Lisa C. Loram<sup>b,c</sup>, Khara Ramos<sup>b,c</sup>, Armando J. de Jesus<sup>a</sup>, Jacob Thomas<sup>d</sup>, Kui Cheng<sup>a</sup>, Anireddy Reddy<sup>b,c</sup>, Andrew A. Somogyi<sup>d</sup>, Mark R. Hutchinson<sup>e</sup>, Linda R. Watkins<sup>b,c</sup>, and Hang Yin<sup>a,c,f,1</sup>

- Morphine binds to MD2 (an accessory protein of TLR4)
- MD2-TLR4 oligomerization
- TLR4 signaling activation
- Release of proinflammatory/neuroexcitatory cytokines (IL-1 $\beta$ )
- Similar mechanism to LPS (endotoxin)

# OPIOIDS: Mu Receptor Binding & TLR4-Signal Activation: Different Rank Order

---

**Mu Receptor**

---

**↑ TLR4 Signal**

---

Buprenorphine

M3G

M6G

Oxycodone

Morphine, methadone

Fentanyl

Fentanyl

Pethidine

Oxycodone

methadone, morphine

Pethidine

Buprenorphine

---

**M3G**

---

**M6G**



(+)-naloxone/ (+)-naltrexone)

(+)-naloxone/ (+)-naltrexone)

---


# Opioid Activation

- Mu receptor: analgesia 
- TLR4/MD2 Signalling: pain 



Opioids have two targets: efficacy & adverse effects in a particular patient may be dependent on which target is predominant

# Tetrapartite Synapse: Microglia, Astrocyte, Pre-synaptic Neuron, Post-Synaptic Neuron



*De Leo et al.  
Pain 122, 17, 2006*



# The Nobel Prize in Physiology or Medicine: 2011




Bruce Beutler



Jules Hoffmann

“for their discovery concerning  
activation of innate immunity”



Ralph Steinman

“for his discovery of the  
dendritic cell and its role  
in adaptive immunity”

# Summary

- Cancer pain → Tissue & Nerve Injury → inflammation
- Tri- (tetra-)partite system: neurons (pre- & post synaptic)-immune cells-glia
- **Direct** Peripheral and Central mechanisms
- Pro-inflammatory cytokine activation from TLR4/MD2 signalling is pivotal: NF- $\kappa$ B → IL-1 $\beta$
- Perhaps a bell-shaped dose-response curve for opioids
- Targeting glial IL-1 $\beta$  release – a potential therapeutic strategy for cancer pain

# Acknowledgements

- Dr Mark Hutchinson, Dr Janet Coller (Adelaide)
- Prof Linda Watkins (Colorado)